{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:35Z","timestamp":1791996755601,"version":"4.4.0"},"reference-count":415,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12072-024-10774-3","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:17:16Z","timestamp":1740673036000},"page":"261-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":177,"title":["The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Mohammed","family":"Eslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Homer","family":"Cua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahinul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Yock","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah-Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soek-Siam","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Boon-bee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang Dao","family":"Viet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley E.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Kamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaigham","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kessarin","family":"Thanapirom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamun","family":"Al Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undram","family":"Lkhagvaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oidov","family":"Baatarkhuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A. M.","family":"Stedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alboraie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Ghazinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Mirijanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemin","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmas Rinaldi Adithya","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Shiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necati","family":"\u00d6rmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"2","key":"10774_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167\u2013228","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3350\/cmh.2021.0310","volume":"28","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150\u2013163","journal-title":"Clin Mol Hepatol"},{"issue":"7308","key":"10774_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","volume":"323","author":"R Harbour","year":"2001","unstructured":"Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334\u2013336","journal-title":"BMJ"},{"issue":"3","key":"10774_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619\u2013629","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10774_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10774_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u20131347","journal-title":"Hepatology"},{"key":"10774_CR7","doi-asserted-by":"crossref","unstructured":"Danpanichkul P, Kongarin S, Permpatdechakul S, Polpichai N, Duangsonk K, Manosroi W, et al. The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019. J Clin Med. 2023;12(20).","DOI":"10.3390\/jcm12206456"},{"issue":"5","key":"10774_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070189","volume":"13","author":"M Chang","year":"2023","unstructured":"Chang M, Shao Z, Shen G. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants. BMJ Open. 2023;13(5): e070189","journal-title":"BMJ Open"},{"issue":"1","key":"10774_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","volume":"21","author":"YL Chen","year":"2021","unstructured":"Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212","journal-title":"BMC Gastroenterol"},{"key":"10774_CR10","doi-asserted-by":"crossref","unstructured":"Prabhakar T, Prasad M, Kumar G, Kaushal K, Shenoy PS, Dubey S, Sarin SK. High prevalence of MAFLD in general population: A large cross\u2010sectional study calls for concerted public health action. Alimentary Pharmacology & Therapeutics. 2024.","DOI":"10.1111\/apt.17892"},{"issue":"2","key":"10774_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jgh3.12044","volume":"2","author":"S Alam","year":"2018","unstructured":"Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open. 2018;2(2):39\u201346","journal-title":"JGH Open."},{"issue":"7","key":"10774_CR12","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/liv.15259","volume":"42","author":"M Kim","year":"2022","unstructured":"Kim M, Yoon EL, Cho S, Lee CM, Kang BK, Park H, et al. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea. Liver Int. 2022;42(7):1536\u20131544","journal-title":"Liver Int"},{"issue":"1","key":"10774_CR13","doi-asserted-by":"publisher","first-page":"13844","DOI":"10.1038\/s41598-021-93435-x","volume":"11","author":"H Fujii","year":"2021","unstructured":"Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, et al. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep. 2021;11(1):13844","journal-title":"Sci Rep"},{"issue":"Suppl1","key":"10774_CR14","first-page":"S102","volume":"14","author":"E Taheri","year":"2021","unstructured":"Taheri E, Moslem A, Mousavi-Jarrahi A, Hatami B, Pourhoseingholi MA, Asadzadeh Aghdaei H, et al. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran. Gastroenterol Hepatol Bed Bench. 2021;14(Suppl1):S102\u2013S111","journal-title":"Gastroenterol Hepatol Bed Bench."},{"issue":"2","key":"10774_CR15","first-page":"37","volume":"2","author":"Y Yilmaz","year":"2021","unstructured":"Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. Hepatol Forum. 2021;2(2):37\u201342","journal-title":"Hepatol Forum."},{"issue":"8","key":"10774_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.5152\/tjg.2021.20512","volume":"32","author":"HT Kani","year":"2021","unstructured":"Kani HT, Demirtas CO, Keklikkiran C, Ergenc I, Mehdiyev S, Akdeniz E, et al. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. Turk J Gastroenterol. 2021;32(8):661\u2013666","journal-title":"Turk J Gastroenterol"},{"issue":"10","key":"10774_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/jgh.16314","volume":"38","author":"K Vaz","year":"2023","unstructured":"Vaz K, Kemp W, Majeed A, Lubel J, Magliano DJ, Glenister KM, et al. Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle. J Gastroenterol Hepatol. 2023;38(10):1823\u20131831","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jgh.15723","volume":"37","author":"W Kemp","year":"2022","unstructured":"Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, et al. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol. 2022;37(2):395\u2013403","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/j.gastro.2019.05.064","volume":"157","author":"M Eslam","year":"2019","unstructured":"Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology. 2019;157(3):590\u2013593","journal-title":"Gastroenterology"},{"key":"10774_CR20","doi-asserted-by":"crossref","unstructured":"Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020.","DOI":"10.1016\/j.jhep.2020.03.039"},{"issue":"3","key":"10774_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251\u2013260","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"10774_CR22","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000435","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee H, Lee HW, Kim SU, Chang KH. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. Clin Transl Gastroenterol. 2022;13(1): e00435","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"10774_CR23","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/liv.16096","volume":"44","author":"Z Pan","year":"2024","unstructured":"Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int. 2024;44(12):3287\u20133289","journal-title":"Liver Int"},{"issue":"6","key":"10774_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919","journal-title":"Hepatol Int"},{"key":"10774_CR25","doi-asserted-by":"crossref","unstructured":"Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, Wu J. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. International journal of environmental research and public health. 2022;19(4).","DOI":"10.3390\/ijerph19042096"},{"issue":"1","key":"10774_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12986-021-00611-x","volume":"18","author":"J Fan","year":"2021","unstructured":"Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab (Lond). 2021;18(1):82","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"10774_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cgh.2015.07.024","volume":"14","author":"D Kim","year":"2016","unstructured":"Kim D, Chung GE, Kwak MS, Seo HB, Kang JH, Kim W, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14(1):132-138.e134","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10774_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u2013651","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10774_CR29","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138\u20132148","journal-title":"Gut"},{"issue":"11\u201312","key":"10774_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15015","volume":"48","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, Aller R, Gallego-Dur\u00e1n R, Banales JM, Crespo J, Garc\u00eda-Monz\u00f3n C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11\u201312):1260\u20131270","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10774_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u2013752","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"10774_CR32","doi-asserted-by":"publisher","first-page":"e1438","DOI":"10.1016\/j.cgh.2021.06.029","volume":"20","author":"D Kim","year":"2022","unstructured":"Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol. 2022;20(6):e1438\u2013e1455","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, Oh SY, Baek HJ, Moon JW, et al. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(2):358-369.e312","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2023.02.004","volume":"52","author":"T Bali","year":"2023","unstructured":"Bali T, Chrysavgis L, Cholongitas E. Metabolic-associated fatty liver disease and sarcopenia. Endocrinol Metab Clin North Am. 2023;52(3):497\u2013508","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"Suppl","key":"10774_CR35","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.3350\/cmh.2022.0358","volume":"29","author":"SK Joo","year":"2023","unstructured":"Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mole Hepatol. 2023;29(Suppl):S68-s78","journal-title":"Clin Mole Hepatol"},{"issue":"5","key":"10774_CR36","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/hep.26716","volume":"59","author":"HC Hong","year":"2014","unstructured":"Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology (Baltimore, MD). 2014;59(5):1772\u20131778","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10774_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123\u2013131","journal-title":"J Hepatol"},{"issue":"9","key":"10774_CR38","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/jgh.16261","volume":"38","author":"E Han","year":"2023","unstructured":"Han E, Chun HS, Lee YH, Lee JS, Lee HW, Kim BK, et al. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study. J Gastroenterol Hepatol. 2023;38(9):1598\u20131609","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cgh.2022.01.020","volume":"21","author":"YC Hsieh","year":"2023","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, et al. Myosteatosis, but not sarcopenia, predisposes nafld subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023;21(2):388-397.e310","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/apt.17601","volume":"58","author":"YK Lee","year":"2023","unstructured":"Lee YK, Koo BK, Joo SK, Lee DH, Jang H, Chai JW, et al. Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD. Aliment Pharmacol Ther. 2023;58(3):322\u2013333","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10774_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3350\/cmh.2023.0035","volume":"29","author":"HK Kim","year":"2023","unstructured":"Kim HK, Bae SJ, Lee MJ, Kim EH, Park H, Kim HS, et al. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity. Clin Moler Hepatol. 2023;29(4):987\u20131001","journal-title":"Clin Moler Hepatol"},{"issue":"5","key":"10774_CR42","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.clnu.2017.08.018","volume":"37","author":"JH Kwak","year":"2018","unstructured":"Kwak JH, Jun DW, Lee SM, Cho YK, Lee KN, Lee HL, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: a cross-sectional study. Clin Nutr. 2018;37(5):1550\u20131557","journal-title":"Clin Nutr"},{"issue":"Suppl","key":"10774_CR43","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3350\/cmh.2022.0398","volume":"29","author":"E Ko","year":"2023","unstructured":"Ko E, Yoon EL, Jun DW. Risk factors in nonalcoholic fatty liver disease. Clin Mole Hepatol. 2023;29(Suppl):S79-s85","journal-title":"Clin Mole Hepatol"},{"key":"10774_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.24920\/004220","volume":"38","author":"YY Wang","year":"2023","unstructured":"Wang YY, Lin HL, Wang KL, Que GX, Cao T, Zhu LM, et al. Influence of gut microbiota and its metabolites on progression of metabolism-associated fatty liver disease. Chin Med Sci J. 2023;38:286","journal-title":"Chin Med Sci J"},{"issue":"16","key":"10774_CR45","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3748\/wjg.v26.i16.1861","volume":"26","author":"J Alharthi","year":"2020","unstructured":"Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol. 2020;26(16):1861","journal-title":"World J Gastroenterol"},{"key":"10774_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/NSS.S398971","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang J, Chen L, Li X, Chen M, Lin T, Chen G. Association between metabolic-associated fatty liver disease and obstructive sleep apnea: a cross-sectional study. Nat Sci Sleep. 2023;15:49\u201357","journal-title":"Nat Sci Sleep"},{"issue":"7","key":"10774_CR47","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1210\/clinem\/dgad016","volume":"108","author":"YL Chen","year":"2023","unstructured":"Chen YL, Tian S, Wu J, Li H, Li S, Xu Z, et al. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2023;108(7):e434\u2013e443","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10774_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ecl.2023.01.005","volume":"52","author":"P Vidal-Cevallos","year":"2023","unstructured":"Vidal-Cevallos P, Mijangos-Trejo A, Uribe M, Tapia NC. The interlink between metabolic-associated fatty liver disease and polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2023;52(3):533\u2013545","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10774_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.23736\/S0391-1977.16.02570-0","volume":"42","author":"G Mintziori","year":"2017","unstructured":"Mintziori G, Poulakos P, Tsametis C, Goulis DG. Hypogonadism and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42(2):145\u2013150","journal-title":"Minerva Endocrinol"},{"issue":"6","key":"10774_CR50","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/jgh.14056","volume":"33","author":"BK Koo","year":"2018","unstructured":"Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33(6):1277\u20131285","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.cgh.2022.02.026","volume":"21","author":"BK Koo","year":"2023","unstructured":"Koo BK, Lee H, Kwak SH, Lee DH, Park JH, Kim W. Long-term effect of pnpla3 on the aggravation of nonalcoholic fatty liver disease in a biopsy-proven cohort. Clin Gastroenterol Hepatol. 2023;21(4):1105-1107.e1103","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"741","key":"10774_CR52","doi-asserted-by":"publisher","first-page":"eadj0133","DOI":"10.1126\/scitranslmed.adj0133","volume":"16","author":"Z Pan","year":"2024","unstructured":"Pan Z, El Sharkway R, Bayoumi A, Metwally M, Gloss BS, Brink R, et al. Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Sci Transl Med. 2024;16(741):eadj0133","journal-title":"Sci Transl Med"},{"issue":"5","key":"10774_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.14348\/molcells.2022.0001","volume":"45","author":"B Kang","year":"2022","unstructured":"Kang B, Kang B, Roh TY, Seong RH, Kim W. The chromatin accessibility landscape of nonalcoholic fatty liver disease progression. Mol Cells. 2022;45(5):343\u2013352","journal-title":"Mol Cells"},{"issue":"1","key":"10774_CR54","doi-asserted-by":"publisher","first-page":"18004","DOI":"10.1038\/s41598-021-97385-2","volume":"11","author":"HK Shin","year":"2021","unstructured":"Shin HK, Park JH, Yu JH, Jin YJ, Suh YJ, Lee JW, et al. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):18004","journal-title":"Sci Rep"},{"issue":"5","key":"10774_CR55","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148\u20131155","journal-title":"J Hepatol"},{"issue":"3","key":"10774_CR56","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","volume":"59","author":"R Pais","year":"2013","unstructured":"Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59(3):550\u2013556","journal-title":"J Hepatol"},{"issue":"6","key":"10774_CR57","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","volume":"79","author":"TG Simon","year":"2023","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Loomba R, Ludvigsson JF. Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study. J Hepatol. 2023;79(6):1366\u20131373","journal-title":"J Hepatol"},{"key":"10774_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep4.1134","volume":"2","author":"P Nasr","year":"2018","unstructured":"Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199\u2013210","journal-title":"Hepatol Commun"},{"issue":"6","key":"10774_CR60","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972\u20131978","journal-title":"Hepatology"},{"issue":"2","key":"10774_CR61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","volume":"20","author":"LA Orci","year":"2022","unstructured":"Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20(2):283-292.e210","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10774_CR62","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/ijc.25797","volume":"128","author":"J Ertle","year":"2011","unstructured":"Ertle J, Dech\u00eane A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128(10):2436\u20132443","journal-title":"Int J Cancer"},{"issue":"18","key":"10774_CR63","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.3390\/cancers13184567","volume":"13","author":"JS Lee","year":"2021","unstructured":"Lee JS, Sinn DH, Park SY, Shin HJ, Lee HW, Kim BK, et al. Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancers (Basel). 2021;13(18):4567","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10774_CR64","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","volume":"61","author":"VW Wong","year":"2012","unstructured":"Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409\u2013415","journal-title":"Gut"},{"issue":"8","key":"10774_CR65","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE Mozes","year":"2023","unstructured":"Mozes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704\u2013713","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"10774_CR66","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12072-023-10550-9","volume":"17","author":"WL Chan","year":"2023","unstructured":"Chan WL, Chong SE, Chang F, Lai LL, Chuah KH, Nik Mustapha NR, et al. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy. Hepatol Int. 2023;17(4):870\u2013881","journal-title":"Hepatol Int"},{"issue":"3","key":"10774_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.7861\/clinmed.2019-0250","volume":"20","author":"A Hussain","year":"2020","unstructured":"Hussain A, Patel PJ, Rhodes F, Srivastava A, Patch D, Rosenberg W. Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. Clin Med (Lond). 2020;20(3):313\u2013318","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10774_CR68","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359\u20131368","journal-title":"Gut"},{"issue":"8","key":"10774_CR69","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jgh.14577","volume":"34","author":"LL Lai","year":"2019","unstructured":"Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol. 2019;34(8):1396\u20131403","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10774_CR70","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):829\u2013836","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10774_CR71","first-page":"1398","volume":"33","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int Off J Int Association Study Liver. 2013;33(9):1398\u20131405","journal-title":"Liver Int Off J Int Association Study Liver"},{"issue":"4","key":"10774_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","volume":"29","author":"VW Wong","year":"2009","unstructured":"Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Alimentary Pharmacol Therapeutics. 2009;29(4):387\u2013396","journal-title":"Alimentary Pharmacol Therapeutics"},{"issue":"2","key":"10774_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.21037\/hbsn.2017.03.06","volume":"6","author":"SY Loo","year":"2017","unstructured":"Loo SY, Chan WK. Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2017;6(2):135\u2013137","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"1","key":"10774_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jhep.2011.03.020","volume":"56","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56(1):234\u2013240","journal-title":"J Hepatol"},{"key":"10774_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.031","author":"SE Mahady","year":"2017","unstructured":"Mahady SE, Macaskill P, Craig JC, Wong GL, Chu WC, Chan HL, et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin Gastroenterol Hepatol. 2017. https:\/\/doi.org\/10.1016\/j.cgh.2017.02.031","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10774_CR76","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE Mozes","year":"2022","unstructured":"Mozes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006\u20131019","journal-title":"Gut"},{"issue":"3","key":"10774_CR77","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","volume":"78","author":"G Cholankeril","year":"2023","unstructured":"Cholankeril G, Kramer JR, Chu J, Yu X, Balakrishnan M, Li L, et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023;78(3):493\u2013500","journal-title":"J Hepatol"},{"issue":"2","key":"10774_CR78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277\u2013286","journal-title":"J Hepatol"},{"issue":"13","key":"10774_CR79","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1007\/s11606-021-07341-z","volume":"37","author":"AD Schreiner","year":"2022","unstructured":"Schreiner AD, Moran WP, Zhang J, Livingston S, Marsden J, Mauldin PD, et al. The association of fibrosis-4 index scores with severe liver outcomes in primary care. J Gen Intern Med. 2022;37(13):3266\u20133274","journal-title":"J Gen Intern Med"},{"issue":"12","key":"10774_CR80","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.cgh.2019.03.006","volume":"17","author":"WK Chan","year":"2019","unstructured":"Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, et al. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019;17(12):2570-2580 e2537","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10774_CR81","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","volume":"76","author":"J Boursier","year":"2022","unstructured":"Boursier J, Hagstrom H, Ekstedt M, Moreau C, Bonacci M, Cure S, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022;76(5):1013\u20131020","journal-title":"J Hepatol"},{"issue":"6","key":"10774_CR82","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/hep.31655","volume":"73","author":"C Cassinotto","year":"2021","unstructured":"Cassinotto C, Boursier J, Paisant A, Guiu B, Irles-Depe M, Canivet C, et al. Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD. Hepatology. 2021;73(6):2196\u20132205","journal-title":"Hepatology"},{"issue":"3","key":"10774_CR83","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(3):626-637.e627","journal-title":"Gastroenterology"},{"issue":"15","key":"10774_CR84","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC, Tsochatzis E, Petta S, Bugianesi E, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331(15):1287\u20131297","journal-title":"JAMA"},{"issue":"2","key":"10774_CR85","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","volume":"71","author":"A Srivastava","year":"2019","unstructured":"Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371\u2013378","journal-title":"J Hepatol"},{"issue":"3","key":"10774_CR86","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","volume":"65","author":"J Boursier","year":"2016","unstructured":"Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):570\u2013578","journal-title":"J Hepatol"},{"issue":"2","key":"10774_CR87","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","volume":"71","author":"J Boursier","year":"2019","unstructured":"Boursier J, Guillaume M, Leroy V, Irles M, Roux M, Lannes A, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71(2):389\u2013396","journal-title":"J Hepatol"},{"issue":"5","key":"10774_CR88","doi-asserted-by":"publisher","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","volume":"116","author":"M Eslam","year":"2021","unstructured":"Eslam M, Wong GL-H, Hashem AM, Chan HL-Y, Nielsen MJ, Leeming DJ, et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Off J Am College Gastroenterol| ACG. 2021;116(5):984\u2013993","journal-title":"Off J Am College Gastroenterol| ACG"},{"key":"10774_CR89","doi-asserted-by":"publisher","first-page":"154958","DOI":"10.1016\/j.metabol.2021.154958","volume":"128","author":"L-J Tang","year":"2022","unstructured":"Tang L-J, Ma H-L, Eslam M, Wong GL-H, Zhu P-W, Chen S-D, et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism. 2022;128:154958","journal-title":"Metabolism"},{"issue":"6","key":"10774_CR90","doi-asserted-by":"publisher","first-page":"e14799","DOI":"10.1111\/dme.14799","volume":"39","author":"L Gracen","year":"2022","unstructured":"Gracen L, Hayward KL, Aikebuse M, Williams S, Russell A, O\u2019Beirne J, et al. An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. Diabet Med. 2022;39(6):e14799","journal-title":"Diabet Med"},{"issue":"12","key":"10774_CR91","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","volume":"72","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yip TC, Wong GL, Leow WX, Liang LY, Lim LL, et al. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. Gut. 2023;72(12):2364\u20132371","journal-title":"Gut"},{"issue":"6","key":"10774_CR92","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","volume":"51","author":"S Dasarathy","year":"2009","unstructured":"Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061\u20131067","journal-title":"J Hepatol"},{"issue":"5","key":"10774_CR93","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u20131030","journal-title":"J Hepatol"},{"issue":"8","key":"10774_CR94","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.cgh.2019.11.060","volume":"18","author":"C Caussy","year":"2020","unstructured":"Caussy C, Brissot J, Singh S, Bassirian S, Hernandez C, Bettencourt R, et al. Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard. Clin Gastroenterol Hepatol. 2020;18(8):1842-1850.e1846","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR95","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2017.05.005","volume":"67","author":"VW Wong","year":"2017","unstructured":"Wong VW, Petta S, Hiriart JB, Camm\u00e0 C, Wong GL, Marra F, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017;67(3):577\u2013584","journal-title":"J Hepatol"},{"issue":"3","key":"10774_CR96","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","volume":"152","author":"CC Park","year":"2017","unstructured":"Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598-607.e592","journal-title":"Gastroenterology"},{"issue":"9","key":"10774_CR97","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","volume":"33","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33(9):1398\u20131405","journal-title":"Liver Int"},{"issue":"7","key":"10774_CR98","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","volume":"72","author":"F Ravaioli","year":"2023","unstructured":"Ravaioli F, Dajti E, Mantovani A, Newsome PN, Targher G, Colecchia A. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut. 2023;72(7):1399\u20131409","journal-title":"Gut"},{"issue":"8","key":"10774_CR99","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714\u2013725","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10774_CR100","doi-asserted-by":"publisher","first-page":"102310","DOI":"10.1016\/j.eclinm.2023.102310","volume":"66","author":"VW-S Wong","year":"2023","unstructured":"Wong VW-S, Anstee QM, Nitze LM, Geerts A, George J, Nolasco V, et al. FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. EClinicalMedicine. 2023;66:102310","journal-title":"EClinicalMedicine."},{"issue":"10","key":"10774_CR101","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","volume":"21","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R. Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(10):2682-2685.e2684","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR102","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","volume":"81","author":"S Gawrieh","year":"2024","unstructured":"Gawrieh S, Vilar-Gomez E, Wilson LA, Pike F, Kleiner DE, Neuschwander-Tetri BA, et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol. 2024;81(4):600\u2013608","journal-title":"J Hepatol"},{"issue":"1","key":"10774_CR103","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(16)30011-5","volume":"1","author":"VW Wong","year":"2016","unstructured":"Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2016;1(1):56\u201367","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"26","key":"10774_CR104","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJM200106283442614","volume":"344","author":"G Spinzi","year":"2001","unstructured":"Spinzi G, Terruzzi V, Minoli G. Liver biopsy. N Engl J Med. 2001;344(26):2030","journal-title":"N Engl J Med"},{"issue":"4","key":"10774_CR105","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1665-2681(19)31343-2","volume":"12","author":"M Eslam","year":"2013","unstructured":"Eslam M, Ampuero J, Jover M, Abd-Elhalim H, Rincon D, Shatat M, et al. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol. 2013;12(4):588\u2013598","journal-title":"Ann Hepatol"},{"issue":"4","key":"10774_CR106","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cld.740","volume":"13","author":"D Berger","year":"2019","unstructured":"Berger D, Desai V, Janardhan S. Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Disease. 2019;13(4):114\u2013116","journal-title":"Clin Liver Disease"},{"issue":"9","key":"10774_CR107","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467\u20132474","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10774_CR108","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"5","key":"10774_CR109","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751\u20131759","journal-title":"Hepatology"},{"issue":"10","key":"10774_CR110","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2(10):e1912565\u2013e1912565","journal-title":"JAMA Netw Open"},{"key":"10774_CR111","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.coph.2021.07.007","volume":"60","author":"Z Pan","year":"2021","unstructured":"Pan Z, Fan J-G, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opinion Pharmacol. 2021;60:170\u2013176","journal-title":"Curr Opinion Pharmacol"},{"issue":"1 Suppl","key":"10774_CR112","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64","journal-title":"J Hepatol"},{"key":"10774_CR113","doi-asserted-by":"publisher","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","volume":"14","author":"RM Pipitone","year":"2023","unstructured":"Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Therapeutic Adv Endocrinol Metab. 2023;14:20420188221145548","journal-title":"Therapeutic Adv Endocrinol Metab"},{"issue":"2","key":"10774_CR114","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329\u2013338","journal-title":"J Clin Transl Hepatol"},{"key":"10774_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433","journal-title":"Metabolism"},{"issue":"3","key":"10774_CR116","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen S, Pang J, Huang R, Xue H, Chen X. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int. 2023;17(3):595\u2013605","journal-title":"Hepatol Int"},{"issue":"4","key":"10774_CR117","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","volume":"18","author":"TY Wang","year":"2022","unstructured":"Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259\u2013268","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10774_CR118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88\u201397","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10774_CR119","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10774_CR120","first-page":"2138","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol Off Clin Prac J Am Gastroenterol Association. 2021;19(10):2138-2147.e2110","journal-title":"Clin Gastroenterol Hepatol Off Clin Prac J Am Gastroenterol Association"},{"key":"10774_CR121","doi-asserted-by":"publisher","first-page":"1078149","DOI":"10.3389\/fendo.2023.1078149","volume":"14","author":"Y Liao","year":"2023","unstructured":"Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, et al. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: a bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1078149","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"18","key":"10774_CR122","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/nu15183970","volume":"15","author":"K Yang","year":"2023","unstructured":"Yang K, Song M. New Insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk. Nutrients. 2023;15(18):3970","journal-title":"Nutrients"},{"issue":"3","key":"10774_CR123","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"D-Q Sun","year":"2023","unstructured":"Sun D-Q, Targher G, Byrne CD, Wheeler DC, Wong VW-S, Fan J-G, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"10774_CR124","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"X-D Zhou","year":"2023","unstructured":"Zhou X-D, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u2013791","journal-title":"Hepatol Int"},{"issue":"5","key":"10774_CR125","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia, Sarcopenia Muscle. 2021;12(5):1168\u20131178","journal-title":"J Cachexia, Sarcopenia Muscle"},{"issue":"5","key":"10774_CR126","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.dsx.2020.06.013","volume":"14","author":"P Sharma","year":"2020","unstructured":"Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metabolic Syndrome. 2020;14(5):825\u2013827","journal-title":"Diabetes Metabolic Syndrome"},{"issue":"1","key":"10774_CR127","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metabolic Syndrome. 2022;14(1):115","journal-title":"Diabetol Metabolic Syndrome"},{"issue":"6","key":"10774_CR128","first-page":"1034","volume":"10","author":"Q Yu","year":"2022","unstructured":"Yu Q, He R, Jiang H, Wu J, Xi Z, He K, et al. Association between Metabolic dysfunction-associated fatty liver disease and cognitive impairment. J Clin Transl Hepatol. 2022;10(6):1034\u20131041","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10774_CR129","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.18632\/oncotarget.22755","volume":"9","author":"J Hu","year":"2018","unstructured":"Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2018;9(2):2752\u20132760","journal-title":"Oncotarget"},{"key":"10774_CR130","doi-asserted-by":"publisher","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","volume":"127","author":"Z Liu","year":"2022","unstructured":"Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metab Clin Exp. 2022;127:154955","journal-title":"Metab Clin Exp"},{"issue":"4","key":"10774_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101344","volume":"48","author":"CY Jung","year":"2022","unstructured":"Jung CY, Koh HB, Park KH, Joo YS, Kim HW, Ahn SH, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: a nationwide cohort study. Diabetes Metab. 2022;48(4): 101344","journal-title":"Diabetes Metab"},{"issue":"3","key":"10774_CR132","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00125-021-05627-9","volume":"65","author":"CY Jung","year":"2022","unstructured":"Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia. 2022;65(3):518\u2013527","journal-title":"Diabetologia"},{"issue":"5","key":"10774_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101362","volume":"48","author":"CY Jung","year":"2022","unstructured":"Jung CY, Chun HS, Lee M, Koh HB, Park KH, Joo YS, et al. Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: a nationwide cohort study. Diabetes Metab. 2022;48(5): 101362","journal-title":"Diabetes Metab"},{"issue":"7","key":"10774_CR134","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/gutjnl-2022-328224","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2023;72(7):1433\u20131436","journal-title":"Gut"},{"issue":"3","key":"10774_CR135","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/liv.15508","volume":"43","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee JS, Lee HW, Kim BK, Park JY, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int. 2023;43(3):608\u2013625","journal-title":"Liver Int"},{"issue":"8","key":"10774_CR136","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mole Sci. 2021;22(8):4156","journal-title":"Int J Mole Sci"},{"issue":"3","key":"10774_CR137","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ecl.2023.01.003","volume":"52","author":"SD Anwar","year":"2023","unstructured":"Anwar SD, Foster C, Ashraf A. Lipid disorders and metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am. 2023;52(3):445\u2013457","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10774_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.122","volume":"48","author":"HS Han","year":"2016","unstructured":"Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Experiment Mole Med. 2016;48(3): e218","journal-title":"Experiment Mole Med"},{"issue":"4","key":"10774_CR139","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136\u20131160","journal-title":"J Hepatol"},{"issue":"6","key":"10774_CR140","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","volume":"14","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metabolic Syndrome. 2020;14(6):1875\u20131887","journal-title":"Diabetes Metabolic Syndrome"},{"issue":"9","key":"10774_CR141","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despres JP, Jha V, Halford JCG, Wei Chieh JT, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743\u2013753","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"10774_CR142","doi-asserted-by":"publisher","first-page":"586","DOI":"10.21037\/hbsn-22-58","volume":"11","author":"M Zoncape","year":"2022","unstructured":"Zoncape M, Liguori A, Tsochatzis EA. Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2022;11(4):586\u2013591","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10774_CR143","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S0168-8278(20)30741-8","volume":"73","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Goyale A, Roccarina D, Prat LI, Guerrero M, Patel R, et al. A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors. J Hepatol. 2020;73:S110","journal-title":"J Hepatol"},{"issue":"4","key":"10774_CR144","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","volume":"10","author":"A Moolla","year":"2019","unstructured":"Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10(4):337\u2013346","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10774_CR145","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/flgastro-2013-100319","volume":"4","author":"JF Cobbold","year":"2013","unstructured":"Cobbold JF, Raveendran S, Peake CM, Anstee QM, Yee MS, Thursz MR. Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. Frontline Gastroenterol. 2013;4(4):263\u2013269","journal-title":"Frontline Gastroenterol"},{"key":"10774_CR146","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/hep.32081","volume":"74","author":"S Kumar","year":"2021","unstructured":"Kumar S, Wong R, Newberry C, Yeung M, Pe\u00f1a J, Sharaiha R. Multi-disciplinary clinic models: a paradigm of care for management of non-alcoholic fatty liver disease (NAFLD). Hepatology. 2021;74:3472","journal-title":"Hepatology"},{"issue":"10","key":"10774_CR147","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","volume":"18","author":"JV Lazarus","year":"2021","unstructured":"Lazarus JV, Anstee QM, Hagstr\u00f6m H, Cusi K, Cortez-Pinto H, Mark HE, et al. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol. 2021;18(10):717\u2013729","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10774_CR148","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despr\u00e9s J-P, Jha V, Halford JC, Chieh JTW, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743\u2013753","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR149","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378 e365","journal-title":"Gastroenterology"},{"issue":"6","key":"10774_CR150","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2337\/dc05-2565","volume":"29","author":"DE Larson-Meyer","year":"2006","unstructured":"Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care. 2006;29(6):1337\u20131344","journal-title":"Diabetes Care"},{"issue":"6","key":"10774_CR151","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2021.11.026","volume":"21","author":"E Tsompanaki","year":"2023","unstructured":"Tsompanaki E, Thanapirom K, Papatheodoridi M, Parikh P, Chotai de Lima Y, Tsochatzis EA. Systematic review and meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(6):1462-1474 e1424","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10774_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156028","volume":"161","author":"X-F Zeng","year":"2024","unstructured":"Zeng X-F, Varady KA, Wang X-D, Targher G, Byrne CD, Tayyem R, et al. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus. Metabolism. 2024;161: 156028","journal-title":"Metabolism"},{"issue":"6","key":"10774_CR153","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/hep.32207","volume":"75","author":"E Vilar-Gomez","year":"2022","unstructured":"Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology. 2022;75(6):1491\u20131506","journal-title":"Hepatology"},{"key":"10774_CR154","doi-asserted-by":"crossref","unstructured":"Laura Sol Grinshpan, Sigal Eilate-Adar, Dana Ivancovsky-Wajcman, Revital Kariv, Michal Gillon-Keren, Zelber-Ragi S. Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: a systematic review. JHEP Reports. 2023;In press.","DOI":"10.1016\/j.jhepr.2023.100964"},{"issue":"5","key":"10774_CR155","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528\u2013562","journal-title":"Endocr Pract"},{"issue":"5","key":"10774_CR156","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u20131835","journal-title":"Hepatology"},{"issue":"5","key":"10774_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100322","volume":"3","author":"SM Francque","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, et al. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 2021;3(5): 100322","journal-title":"JHEP Rep"},{"issue":"2","key":"10774_CR158","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","volume":"38","author":"M Plauth","year":"2019","unstructured":"Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schutz T, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38(2):485\u2013521","journal-title":"Clin Nutr"},{"issue":"5","key":"10774_CR159","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.30076","volume":"68","author":"C Properzi","year":"2018","unstructured":"Properzi C, O\u2019Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, et al. Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology. 2018;68(5):1741\u20131754","journal-title":"Hepatology"},{"issue":"3","key":"10774_CR160","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0041-1723751","volume":"41","author":"T Kawaguchi","year":"2021","unstructured":"Kawaguchi T, Charlton M, Kawaguchi A, Yamamura S, Nakano D, Tsutsumi T, et al. Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Semin Liver Dis. 2021;41(3):225\u2013234","journal-title":"Semin Liver Dis"},{"issue":"9","key":"10774_CR161","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","volume":"41","author":"L Haigh","year":"2022","unstructured":"Haigh L, Kirk C, El Gendy K, Gallacher J, Errington L, Mathers JC, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41(9):1913\u20131931","journal-title":"Clin Nutr"},{"issue":"10","key":"10774_CR162","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/nu15102250","volume":"15","author":"C Del Bo","year":"2023","unstructured":"Del Bo C, Perna S, Allehdan S, Rafique A, Saad S, AlGhareeb F, et al. Does the Mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials. Nutrients. 2023;15(10):2250","journal-title":"Nutrients"},{"issue":"2","key":"10774_CR163","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hep.30362","volume":"70","author":"Y Ma","year":"2019","unstructured":"Ma Y, Yang W, Simon TG, Smith-Warner SA, Fung TT, Sui J, et al. Dietary patterns and risk of hepatocellular carcinoma among us men and women. Hepatology. 2019;70(2):577\u2013586","journal-title":"Hepatology"},{"issue":"8","key":"10774_CR164","doi-asserted-by":"publisher","first-page":"e0212","DOI":"10.1097\/HC9.0000000000000212","volume":"7","author":"M Lange","year":"2023","unstructured":"Lange M, Nadkarni D, Martin L, Newberry C, Kumar S, Kushner T. Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Commun. 2023;7(8):e0212","journal-title":"Hepatol Commun"},{"key":"10774_CR165","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fendo.2020.00607","volume":"11","author":"GM Cunha","year":"2020","unstructured":"Cunha GM, Guzman G, Correa De Mello LL, Trein B, Spina L, Bussade I, et al. Efficacy of a 2-month very low-calorie ketogenic diet (VLCKD) compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity. Front Endocrinol (Lausanne). 2020;11:607","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"10774_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100256","volume":"3","author":"M Holmer","year":"2021","unstructured":"Holmer M, Lindqvist C, Petersson S, Moshtaghi-Svensson J, Tillander V, Brismar TB, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial. JHEP Rep. 2021;3(3): 100256","journal-title":"JHEP Rep."},{"issue":"9","key":"10774_CR167","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.cgh.2021.09.042","volume":"20","author":"S Niezen","year":"2022","unstructured":"Niezen S, Mehta M, Jiang ZG, Tapper EB. Coffee consumption is associated with lower liver stiffness: a nationally representative study. Clin Gastroenterol Hepatol. 2022;20(9):2032-2040 e2036","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10774_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.08.071","volume":"20","author":"U Hayat","year":"2021","unstructured":"Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20: 100254","journal-title":"Ann Hepatol"},{"issue":"6","key":"10774_CR169","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/bjsm.2010.083469","volume":"45","author":"R Sallis","year":"2011","unstructured":"Sallis R. Developing healthcare systems to support exercise: exercise as the fifth vital sign. British J Sports Med. 2011;45(6):473\u2013474","journal-title":"British J Sports Med"},{"issue":"12","key":"10774_CR170","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s40279-023-01918-w","volume":"53","author":"SE Keating","year":"2023","unstructured":"Keating SE, Sabag A, Hallsworth K, Hickman IJ, Macdonald GA, Stine JG, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science Australia. Sports Med. 2023;53(12):2347\u20132371","journal-title":"Sports Med"},{"issue":"9","key":"10774_CR171","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1249\/MSS.0000000000003199","volume":"55","author":"JG Stine","year":"2023","unstructured":"Stine JG, Long MT, Corey KE, Sallis RE, Allen AM, Armstrong MJ, et al. Physical activity and nonalcoholic fatty liver disease: a roundtable statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2023;55(9):1717\u20131726","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"10774_CR172","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/1756283X16638830","volume":"9","author":"S Zelber-Sagi","year":"2016","unstructured":"Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016;9(3):392\u2013407","journal-title":"Therap Adv Gastroenterol."},{"issue":"27","key":"10774_CR173","doi-asserted-by":"publisher","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","volume":"22","author":"P Golabi","year":"2016","unstructured":"Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review. World J Gastroenterol. 2016;22(27):6318\u20136327","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10774_CR174","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","volume":"134","author":"KM Korenblat","year":"2008","unstructured":"Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134(5):1369\u20131375","journal-title":"Gastroenterology"},{"issue":"2","key":"10774_CR175","doi-asserted-by":"publisher","first-page":"E552","DOI":"10.1152\/ajpendo.00220.2009","volume":"297","author":"TP Solomon","year":"2009","unstructured":"Solomon TP, Haus JM, Marchetti CM, Stanley WC, Kirwan JP. Effects of exercise training and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance. Am J Physiol Endocrinol Metab. 2009;297(2):E552-559","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2 Suppl","key":"10774_CR176","doi-asserted-by":"publisher","first-page":"558S","DOI":"10.1093\/ajcn\/72.2.558S","volume":"72","author":"JF Horowitz","year":"2000","unstructured":"Horowitz JF, Klein S. Lipid metabolism during endurance exercise. Am J Clin Nutr. 2000;72(2 Suppl):558S-563S","journal-title":"Am J Clin Nutr"},{"issue":"89","key":"10774_CR177","doi-asserted-by":"publisher","first-page":"eadi5377","DOI":"10.1126\/sciimmunol.adi5377","volume":"8","author":"PK Langston","year":"2023","unstructured":"Langston PK, Sun Y, Ryback BA, Mueller AL, Spiegelman BM, Benoist C, et al. Regulatory T cells shield muscle mitochondria from interferon-gamma-mediated damage to promote the beneficial effects of exercise. Sci Immunol. 2023;8(89):eadi5377","journal-title":"Sci Immunol."},{"issue":"1","key":"10774_CR178","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cgh.2016.07.031","volume":"15","author":"D Houghton","year":"2017","unstructured":"Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2017;15(1):96-102 e103","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10774_CR179","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, et al. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2021;19(11):2274-2283 e2275","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR180","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","volume":"63","author":"SE Keating","year":"2015","unstructured":"Keating SE, Hackett DA, Parker HM, O\u2019Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63(1):174\u2013182","journal-title":"J Hepatol"},{"issue":"3","key":"10774_CR181","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/clinem\/dgab795","volume":"107","author":"A Sabag","year":"2022","unstructured":"Sabag A, Barr L, Armour M, Armstrong A, Baker CJ, Twigg SM, et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107(3):862\u2013881","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10774_CR182","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","volume":"176","author":"HJ Zhang","year":"2016","unstructured":"Zhang HJ, He J, Pan LL, Ma ZM, Han CK, Chen CS, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med. 2016;176(8):1074\u20131082","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10774_CR183","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s10620-022-07779-z","volume":"68","author":"SE Keating","year":"2023","unstructured":"Keating SE, Croci I, Wallen MP, Cox ER, Thuzar M, Pham U, et al. High-intensity interval training is safe, feasible and efficacious in nonalcoholic steatohepatitis: a randomized controlled trial. Dig Dis Sci. 2023;68(5):2123\u20132139","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10774_CR184","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.15989","volume":"52","author":"P O'Gorman","year":"2020","unstructured":"O\u2019Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ni Fhloinn D, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52(8):1387\u20131398","journal-title":"Aliment Pharmacol Ther"},{"key":"10774_CR185","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/liv.15769","volume":"44","author":"SJ Harris","year":"2023","unstructured":"Harris SJ, Smith N, Hummer B, Schreibman IR, Faust AJ, Geyer NR, et al. Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis. Liver Int. 2023;44:532","journal-title":"Liver Int"},{"issue":"7","key":"10774_CR186","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","volume":"118","author":"JG Stine","year":"2023","unstructured":"Stine JG, DiJoseph K, Pattison Z, Harrington A, Chinchilli VM, Schmitz KH, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2023;118(7):1204\u20131213","journal-title":"Am J Gastroenterol"},{"key":"10774_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.774030","volume":"8","author":"V Zambon Azevedo","year":"2021","unstructured":"Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of sarcopenia on the severity of the liver damage in patients with non-alcoholic fatty liver disease. Front Nutr. 2021;8: 774030","journal-title":"Front Nutr"},{"key":"10774_CR188","doi-asserted-by":"publisher","DOI":"10.1139\/apnm-2020-0245","author":"R El-Kotob","year":"2020","unstructured":"El-Kotob R, Ponzano M, Chaput JP, Janssen I, Kho ME, Poitras VJ, et al. Resistance training and health in adults: an overview of systematic reviews. Appl Physiol Nutr Metab. 2020. https:\/\/doi.org\/10.1139\/apnm-2020-0245","journal-title":"Appl Physiol Nutr Metab"},{"issue":"1","key":"10774_CR189","first-page":"e00001","volume":"1","author":"S Abou Sawan","year":"2023","unstructured":"Abou Sawan S, Nunes EA, Lim C, McKendry J, Phillips SM. The health benefits of resistance exercise: beyond hypertrophy and big weights. Exercise Sports Movement. 2023;1(1):e00001","journal-title":"Exercise Sports Movement"},{"issue":"1","key":"10774_CR190","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","volume":"66","author":"R Hashida","year":"2017","unstructured":"Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66(1):142\u2013152","journal-title":"J Hepatol"},{"issue":"5","key":"10774_CR191","first-page":"1050","volume":"11","author":"SE Keating","year":"2023","unstructured":"Keating SE, Croci I, Wallen MP, Cox ER, Coombes JS, Burton NW, et al. High-intensity Interval training for the management of nonalcoholic steatohepatitis: participant experiences and perspectives. J Clin Transl Hepatol. 2023;11(5):1050\u20131060","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"10774_CR192","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1007\/s10620-020-06673-w","volume":"66","author":"JG Stine","year":"2021","unstructured":"Stine JG, Soriano C, Schreibman I, Rivas G, Hummer B, Yoo E, et al. Breaking down barriers to physical activity in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2021;66(10):3604\u20133611","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10774_CR193","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/hep4.1808","volume":"6","author":"O Glass","year":"2022","unstructured":"Glass O, Liu D, Bechard E, Guy CD, Pendergast J, Mae Diehl A, et al. Perceptions of exercise and its challenges in patients with nonalcoholic fatty liver disease: a survey-based study. Hepatol Commun. 2022;6(2):334\u2013344","journal-title":"Hepatol Commun"},{"issue":"3","key":"10774_CR194","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cgh.2021.03.017","volume":"20","author":"P Jirapinyo","year":"2022","unstructured":"Jirapinyo P, McCarty TR, Dolan RD, Shah R, Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):511-524 e511","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10774_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.880749","volume":"9","author":"SY Lee","year":"2022","unstructured":"Lee SY, Lai H, Chua YJ, Wang MX, Lee GH. Endoscopic bariatric and metabolic therapies and their effects on metabolic syndrome and non-alcoholic fatty liver disease - a systematic review and meta-analysis. Front Med (Lausanne). 2022;9: 880749","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"10774_CR196","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","volume":"32","author":"H Zhou","year":"2022","unstructured":"Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes Surg. 2022;32(6):1872\u20131883","journal-title":"Obes Surg"},{"issue":"7","key":"10774_CR197","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003206","volume":"17","author":"T Wiggins","year":"2020","unstructured":"Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17(7): e1003206","journal-title":"PLoS Med"},{"issue":"12","key":"10774_CR198","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","volume":"18","author":"D Eisenberg","year":"2022","unstructured":"Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345\u20131356","journal-title":"Surg Obes Relat Dis."},{"issue":"2","key":"10774_CR199","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","volume":"149","author":"G Lassailly","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379\u2013388","journal-title":"Gastroenterology"},{"issue":"6","key":"10774_CR200","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040\u201310601011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10390","key":"10774_CR201","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786\u20131797","journal-title":"Lancet"},{"issue":"4","key":"10774_CR202","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301 e1295","journal-title":"Gastroenterology"},{"issue":"20","key":"10774_CR203","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031\u20132042","journal-title":"JAMA"},{"issue":"5","key":"10774_CR204","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s00268-021-06382-z","volume":"46","author":"J Bai","year":"2022","unstructured":"Bai J, Jia Z, Chen Y, Li Y, Zheng S, Duan Z. Bariatric surgery is effective and safe for obese patients with compensated cirrhosis: a systematic review and meta-analysis. World J Surg. 2022;46(5):1122\u20131133","journal-title":"World J Surg"},{"issue":"3","key":"10774_CR205","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","volume":"17","author":"L Agarwal","year":"2021","unstructured":"Agarwal L, Sahu AK, Baksi A, Agarwal A, Aggarwal S. Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. Surg Obes Relat Dis. 2021;17(3):525\u2013537","journal-title":"Surg Obes Relat Dis."},{"issue":"22","key":"10774_CR206","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297\u20132307","journal-title":"N Engl J Med"},{"issue":"5","key":"10774_CR207","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305\u2013315","journal-title":"Ann Intern Med"},{"issue":"5","key":"10774_CR208","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","volume":"15","author":"J-F Huang","year":"2021","unstructured":"Huang J-F, Dai C-Y, Huang C-F, Tsai P-C, Yeh M-L, Hsu P-Y, et al. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int. 2021;15(5):1136\u20131147","journal-title":"Hepatol Int"},{"issue":"8","key":"10774_CR209","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801\u20131808","journal-title":"Diabetes Care"},{"issue":"4","key":"10774_CR210","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812\u2013821","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10774_CR211","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285\u2013292","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10774_CR212","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1111\/jgh.15580","volume":"36","author":"S Phrueksotsai","year":"2021","unstructured":"Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S, et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36(10):2952\u20132959","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10774_CR213","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4 placebo-controlled trial. Diabetes Care. 2020;43(2):298\u2013305","journal-title":"Diabetes Care"},{"issue":"2","key":"10774_CR214","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","volume":"65","author":"LL Lai","year":"2020","unstructured":"Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65(2):623\u2013631","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10774_CR215","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","volume":"28","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022;28(7):1432\u20131438","journal-title":"Nat Med"},{"issue":"8","key":"10774_CR216","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc19-0167","volume":"42","author":"F Bril","year":"2019","unstructured":"Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481\u20131488","journal-title":"Diabetes Care"},{"issue":"2","key":"10774_CR217","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hep.30368","volume":"71","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495\u2013509","journal-title":"Hepatology"},{"issue":"14","key":"10774_CR218","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2011;306(14):1549\u20131556","journal-title":"JAMA"},{"issue":"7","key":"10774_CR219","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/00365520902845268","volume":"44","author":"JW Haukeland","year":"2009","unstructured":"Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853\u2013860","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10774_CR220","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.23623","volume":"52","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79\u2013104","journal-title":"Hepatology"},{"issue":"16","key":"10774_CR221","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659\u20131668","journal-title":"JAMA"},{"issue":"1","key":"10774_CR222","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/br.2012.18","volume":"1","author":"Y Li","year":"2013","unstructured":"Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013;1(1):57\u201364","journal-title":"Biomed Rep."},{"key":"10774_CR223","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cgh.2020.04.083","volume":"19","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Eslam M, et al. Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related child-pugh a cirrhosis. Clin Gastroenterol Hepatol. 2020;19:136","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR224","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.aohep.2019.11.008","volume":"19","author":"J Zhou","year":"2020","unstructured":"Zhou J, Ke Y, Lei X, Wu T, Li Y, Bao T, et al. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Ann Hepatol. 2020;19(3):320\u2013328","journal-title":"Ann Hepatol"},{"issue":"4","key":"10774_CR225","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"184","author":"H Jang","year":"2024","unstructured":"Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S, et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med. 2024;184(4):375\u2013383","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10774_CR226","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","volume":"98","author":"SA Harrison","year":"2003","unstructured":"Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485\u20132490","journal-title":"Am J Gastroenterol"},{"issue":"18","key":"10774_CR227","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u20131685","journal-title":"N Engl J Med"},{"issue":"2","key":"10774_CR228","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.12352","volume":"38","author":"JH Hoofnagle","year":"2013","unstructured":"Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38(2):134\u2013143","journal-title":"Aliment Pharmacol Ther"},{"issue":"7\u20138","key":"10774_CR229","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.nut.2014.11.018","volume":"31","author":"K Sato","year":"2015","unstructured":"Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31(7\u20138):923\u2013930","journal-title":"Nutrition"},{"issue":"3","key":"10774_CR230","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4103\/1319-3767.132983","volume":"20","author":"AA Sarkhy","year":"2014","unstructured":"Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol. 2014;20(3):143\u2013153","journal-title":"Saudi J Gastroenterol."},{"issue":"1129","key":"10774_CR231","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/postgradmedj-2018-136364","volume":"95","author":"I Amanullah","year":"2019","unstructured":"Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019;95(1129):601\u2013611","journal-title":"Postgrad Med J"},{"issue":"2","key":"10774_CR232","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/hep.32294","volume":"76","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469\u2013482","journal-title":"Hepatology"},{"issue":"3","key":"10774_CR233","first-page":"979","volume":"35","author":"GB Goh","year":"2015","unstructured":"Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int Off J Int Association Study Liver. 2015;35(3):979\u2013985","journal-title":"Liver Int Off J Int Association Study Liver"},{"issue":"11","key":"10774_CR234","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/jama.2024.1215","volume":"331","author":"TG Simon","year":"2024","unstructured":"Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA. 2024;331(11):920\u2013929","journal-title":"JAMA"},{"key":"10774_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87: 104392","journal-title":"EBioMedicine"},{"issue":"10","key":"10774_CR236","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","volume":"41","author":"C Boutari","year":"2022","unstructured":"Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins\u2019 efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Nutr (Edinburgh, Scotland). 2022;41(10):2195\u20132206","journal-title":"Clin Nutr (Edinburgh, Scotland)."},{"issue":"1","key":"10774_CR237","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","volume":"20","author":"Y Cho","year":"2022","unstructured":"Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022;20(1):93","journal-title":"BMC Med"},{"issue":"Suppl 1","key":"10774_CR238","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(23)00440-3","volume":"78","author":"S Harrison","year":"2023","unstructured":"Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al. Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis. J Hepatol. 2023;78(Suppl 1):S1","journal-title":"J Hepatol"},{"issue":"11","key":"10774_CR239","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u20132928","journal-title":"Nat Med"},{"issue":"6","key":"10774_CR240","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79(6):1557\u20131565","journal-title":"J Hepatol"},{"issue":"12","key":"10774_CR241","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u20131124","journal-title":"N Engl J Med"},{"issue":"6","key":"10774_CR242","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjaer MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u2013522","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"10774_CR243","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"key":"10774_CR244","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311","journal-title":"N Engl J Med"},{"issue":"4","key":"10774_CR245","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. New Engl J Med. 2024;391(4):311\u2013319","journal-title":"New Engl J Med"},{"issue":"17","key":"10774_CR246","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"12","key":"10774_CR247","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080\u20131093","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"10774_CR248","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998\u20131008","journal-title":"N Engl J Med"},{"issue":"30","key":"10774_CR249","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","volume":"24","author":"S Leoni","year":"2018","unstructured":"Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroentero. 2018;24(30):3361","journal-title":"World J Gastroentero"},{"issue":"6","key":"10774_CR250","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM, et al. association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625.e1612","journal-title":"Gastroenterology"},{"issue":"5","key":"10774_CR251","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657\u20131669","journal-title":"Gastroenterology"},{"issue":"10","key":"10774_CR252","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, et al. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)\/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clin Gastroenterol Hepatol. 2022;20(10):2296-2306 e2296","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10774_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100370","volume":"3","author":"LL Gronkjaer","year":"2021","unstructured":"Gronkjaer LL, Lauridsen MM. Quality of life and unmet needs in patients with chronic liver disease: a mixed-method systematic review. JHEP Rep. 2021;3(6): 100370","journal-title":"JHEP Rep."},{"issue":"12","key":"10774_CR254","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(12):2552-2560 e2510","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR255","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.9609","volume":"21","author":"AM Beleigoli","year":"2019","unstructured":"Beleigoli AM, Andrade AQ, Cancado AG, Paulo MN, Diniz MFH, Ribeiro AL. Web-based digital health interventions for weight loss and lifestyle habit changes in overweight and obese adults: systematic review and meta-analysis. J Med Internet Res. 2019;21(1): e298","journal-title":"J Med Internet Res"},{"key":"10774_CR256","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","volume":"22","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Johansen S, Hansen JK, Andersen P, et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin Gastroenterol Hepatol. 2023;22:1037","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10774_CR257","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809\u20132817","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10774_CR258","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/apt.15679","volume":"51","author":"R Loomba","year":"2020","unstructured":"Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of medicare data. Alimentary Pharmacol Therap. 2020;51(11):1149\u20131159","journal-title":"Alimentary Pharmacol Therap"},{"issue":"1","key":"10774_CR259","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"9","key":"10774_CR260","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cgh.2012.05.008","volume":"10","author":"FD Mendes","year":"2012","unstructured":"Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(9):1028\u20131033","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10774_CR261","first-page":"1449","volume":"22","author":"S Francque","year":"2010","unstructured":"Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol. 2010;22(12):1449\u20131457","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR262","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-017-0966-6","volume":"15","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med. 2017;15(1):200","journal-title":"BMC Med"},{"issue":"2","key":"10774_CR263","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1586\/egh.12.83","volume":"7","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013;7(2):141\u2013155","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10774_CR264","doi-asserted-by":"publisher","first-page":"979","DOI":"10.14218\/JCTH.2021.00593","volume":"10","author":"SHH Nababan","year":"2022","unstructured":"Nababan SHH, Lesmana CRA. Portal hypertension in nonalcoholic fatty liver disease: from pathogenesis to clinical practice. J Clin Transl Hepatol. 2022;10(5):979\u2013985","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10774_CR265","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/poh2.19","volume":"1","author":"CRA Lesmana","year":"2022","unstructured":"Lesmana CRA, Nababan SH, Kalista KF, Kurniawan J, Jasirwan COM, Sulaiman AS, et al. Impact of endoscopic ultrasound examination for deep esophageal collateral veins evaluation in liver cirrhosis patients prior to endoscopic treatment: a case series. Portal Hypertension Cirrhosis. 2022;1(1):76\u201381","journal-title":"Portal Hypertension Cirrhosis."},{"issue":"12","key":"10774_CR266","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6658","volume":"10","author":"CRA Lesmana","year":"2022","unstructured":"Lesmana CRA. Technique innovation of endoscopic ultrasound portal pressure gradient measurement using standard manometer set for portal hypertension assessment. Clin Case Rep. 2022;10(12): e6658","journal-title":"Clin Case Rep."},{"key":"10774_CR267","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/poh2.74","volume":"3","author":"CRA Lesmana","year":"2024","unstructured":"Lesmana CRA, Kalista KF, Nababan SHH, Kurniawan J, Jasirwan COM, Sulaiman AS, et al. Innovations in endoscopic ultrasound for portal hypertension and its role in managing complications in clinical practice: lessons learned from a tertiary referral public hospital. Portal Hypertension Cirrhosis. 2024;3:31","journal-title":"Portal Hypertension Cirrhosis."},{"issue":"1","key":"10774_CR268","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","volume":"144","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garc\u00eda-Pag\u00e1n JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144(1):102\u2013111","journal-title":"Gastroenterology"},{"issue":"8","key":"10774_CR269","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.cgh.2023.08.004","volume":"22","author":"M Pons","year":"2024","unstructured":"Pons M, Rivera-Esteban J, Ma MM, Davyduke T, Delamarre A, Hermabessi\u00e8re P, et al. Point-of-care noninvasive prediction of liver-related events in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2024;22(8):1637\u20131645","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR270","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Off J Am College Gastroenterol ACG. 2021;116(4):723\u2013732","journal-title":"Off J Am College Gastroenterol ACG"},{"issue":"4","key":"10774_CR271","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta S, Sebastiani G, Vigano M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19(4):806\u2013815","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR272","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.dld.2022.10.009","volume":"55","author":"D Segna","year":"2023","unstructured":"Segna D, Mendoza YP, Lange NF, Rodrigues SG, Berzigotti A. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update. Dig Liver Dis. 2023;55(3):326\u2013335","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10774_CR273","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/apt.17699","volume":"58","author":"H Lin","year":"2023","unstructured":"Lin H, Lai JC, Wong GL, Delamarre A, Ahn SH, Li G, et al. Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: a competing risk analysis. Aliment Pharmacol Ther. 2023;58(9):920\u2013928","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10774_CR274","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","volume":"117","author":"E Dajti","year":"2022","unstructured":"Dajti E, Ravaioli F, Marasco G, Alemanni LV, Colecchia L, Ferrarese A, et al. A combined baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2022;117(11):1825\u20131833","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10774_CR275","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.cgh.2022.06.007","volume":"21","author":"M Jachs","year":"2023","unstructured":"Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol. 2023;21(9):2318\u20132326","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR276","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s12072-021-10281-9","volume":"16","author":"YG Chen","year":"2022","unstructured":"Chen YG, Yang CW, Chung CH, Ho CL, Chen WL, Chien WC. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. 2022;16(4):807\u2013816","journal-title":"Hepatol Int"},{"issue":"1","key":"10774_CR277","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12876-023-02851-y","volume":"23","author":"Y Johira","year":"2023","unstructured":"Johira Y, Nakahara T, Kinami T, Yamasaki S, Kosaka M, Shirane Y, et al. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study. BMC Gastroenterol. 2023;23(1):222","journal-title":"BMC Gastroenterol"},{"key":"10774_CR278","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816472","volume":"12","author":"YP Lin","year":"2022","unstructured":"Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, et al. Metabolic risks are increasing in non-B non-C early-stage hepatocellular carcinoma: a 10-year follow-up study. Front Oncol. 2022;12: 816472","journal-title":"Front Oncol"},{"issue":"2","key":"10774_CR279","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100231","volume":"3","author":"S Myers","year":"2021","unstructured":"Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2): 100231","journal-title":"JHEP Rep."},{"issue":"6","key":"10774_CR280","doi-asserted-by":"publisher","first-page":"941","DOI":"10.21037\/hbsn-23-538","volume":"12","author":"S Shimose","year":"2023","unstructured":"Shimose S, Tsutsumi T, Nakano D, Sano T, Amano K, Kawaguchi T. An ever-increasing metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: what are problems and countermeasures? Hepatobiliary Surg Nutr. 2023;12(6):941\u2013944","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"1","key":"10774_CR281","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2021-324915","volume":"72","author":"A Vitale","year":"2023","unstructured":"Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database. Gut. 2023;72(1):141\u2013152","journal-title":"Gut"},{"issue":"7","key":"10774_CR282","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/liv.15577","volume":"43","author":"S Pelusi","year":"2023","unstructured":"Pelusi S, Bianco C, Colombo M, Cologni G, Del Poggio P, Pugliese N, et al. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. Liver Int. 2023;43(7):1593\u20131603","journal-title":"Liver Int"},{"issue":"4","key":"10774_CR283","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/hepr.13993","volume":"54","author":"T Sano","year":"2023","unstructured":"Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, et al. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study. Hepatol Res. 2023;54(4):326\u201335.","journal-title":"Hepatol Res"},{"issue":"5","key":"10774_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5): 100350","journal-title":"JHEP Rep."},{"issue":"20","key":"10774_CR285","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.3390\/cancers14205002","volume":"14","author":"B Yun","year":"2022","unstructured":"Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Prognostic impact of MAFLD following surgical resection of hepatitis B virus-related hepatocellular carcinoma: a nationwide cohort Study. Cancers (Basel). 2022;14(20):5002","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10774_CR286","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u20131149","journal-title":"Hepatol Int"},{"key":"10774_CR287","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2147\/CMAR.S368366","volume":"14","author":"J Xue","year":"2022","unstructured":"Xue J, Wang QX, Xiao HM, Shi MJ, Xie YB, Li S, et al. Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis b virus-related hepatocellular carcinoma based on propensity score matching analysis. Cancer Manag Res. 2022;14:2193\u20132202","journal-title":"Cancer Manag Res."},{"issue":"12","key":"10774_CR288","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hepr.13830","volume":"52","author":"B Yun","year":"2022","unstructured":"Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study. Hepatol Res. 2022;52(12):975\u2013984","journal-title":"Hepatol Res"},{"key":"10774_CR289","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejim.2022.11.012","volume":"107","author":"DPC van der Spek","year":"2023","unstructured":"van der Spek DPC, Katwaroe WK, van Kleef LA, Brakenhoff S, de Man RA, de Knegt RJ, et al. Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980\u20132020. Eur J Intern Med. 2023;107:86\u201392","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10774_CR290","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.34637","volume":"153","author":"MN Kim","year":"2023","unstructured":"Kim MN, Han K, Yoo J, Hwang SG, Zhang X, Ahn SH. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023;153(8):1448\u20131458","journal-title":"Int J Cancer"},{"issue":"3","key":"10774_CR291","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u2013693","journal-title":"J Hepatol"},{"issue":"2","key":"10774_CR292","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00043426-199205000-00005","volume":"14","author":"PC Prorok","year":"1992","unstructured":"Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol. 1992;14(2):117\u2013128","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"4","key":"10774_CR293","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14737140.2022.2052276","volume":"22","author":"B Stefanini","year":"2022","unstructured":"Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther. 2022;22(4):371\u2013381","journal-title":"Expert Rev Anticancer Ther"},{"issue":"47","key":"10774_CR294","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.3748\/wjg.v19.i47.8808","volume":"19","author":"EG Giannini","year":"2013","unstructured":"Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol. 2013;19(47):8808\u20138821","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10774_CR295","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u20131965","journal-title":"Hepatology"},{"issue":"1","key":"10774_CR296","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"4","key":"10774_CR297","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u2013370","journal-title":"Hepatol Int"},{"issue":"6","key":"10774_CR298","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","volume":"75","author":"GN Ioannou","year":"2021","unstructured":"Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476\u20131484","journal-title":"J Hepatol"},{"issue":"6","key":"10774_CR299","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828\u20131837","journal-title":"Gastroenterology"},{"issue":"20","key":"10774_CR300","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.3390\/jcm10204638","volume":"10","author":"M Castellana","year":"2021","unstructured":"Castellana M, Donghia R, Lampignano L, Castellana F, Zupo R, Sardone R, et al. Prevalence of the absence of cirrhosis in subjects with nafld-associated hepatocellular carcinoma. J Clin Med. 2021;10(20):4638","journal-title":"J Clin Med"},{"issue":"3","key":"10774_CR301","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","volume":"18","author":"J Best","year":"2020","unstructured":"Best J, Bechmann LP, Sowa JP, Sydor S, Dechene A, Pflanz K, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;18(3):728\u2013735","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR302","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2021.08.028","volume":"76","author":"AG Singal","year":"2022","unstructured":"Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022;76(1):195\u2013201","journal-title":"J Hepatol"},{"issue":"2","key":"10774_CR303","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12(2):558\u2013580","journal-title":"Acta Pharm Sin B."},{"issue":"10","key":"10774_CR304","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/hepr.13808","volume":"52","author":"S Inamine","year":"2022","unstructured":"Inamine S, Kage M, Akiba J, Kawaguchi T, Yoshio S, Kawaguchi M, et al. Metabolic dysfunction-associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients. Hepatol Res. 2022;52(10):841\u2013858","journal-title":"Hepatol Res"},{"issue":"4","key":"10774_CR305","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/hepr.13993","volume":"54","author":"T Sano","year":"2024","unstructured":"Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, et al. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study. Hepatol Res. 2024;54(4):326\u2013335","journal-title":"Hepatol Res"},{"issue":"4","key":"10774_CR306","first-page":"356","volume":"51","author":"A Fahira","year":"2019","unstructured":"Fahira A, Hanifah RS, Wardoyo MP, Diba AD, Ramadhan R, Barliana JD, et al. Is higher BMI associated with worse overall mortality in hepatocellular carcinoma patients? An evidence based case report. Acta Med Indones. 2019;51(4):356\u2013363","journal-title":"Acta Med Indones"},{"issue":"1","key":"10774_CR307","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jhep.2015.02.031","volume":"63","author":"N Fujiwara","year":"2015","unstructured":"Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131\u2013140","journal-title":"J Hepatol"},{"key":"10774_CR308","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12957-015-0713-4","volume":"13","author":"Q Li","year":"2015","unstructured":"Li Q, Xing H, Liu D, Li H. Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. World J Surg Oncol. 2015;13:294","journal-title":"World J Surg Oncol."},{"issue":"3","key":"10774_CR309","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/hepr.13453","volume":"50","author":"K Hirota","year":"2020","unstructured":"Hirota K, Kawaguchi T, Koya S, Nagamatsu A, Tomita M, Hashida R, et al. Clinical utility of the liver frailty index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma. Hepatol Res. 2020;50(3):330\u2013341","journal-title":"Hepatol Res"},{"issue":"12","key":"10774_CR310","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/hepr.13405","volume":"49","author":"A Nagamatsu","year":"2019","unstructured":"Nagamatsu A, Kawaguchi T, Hirota K, Koya S, Tomita M, Hashida R, et al. Slow walking speed overlapped with low handgrip strength in chronic liver disease patients with hepatocellular carcinoma. Hepatol Res. 2019;49(12):1427\u20131440","journal-title":"Hepatol Res"},{"issue":"3","key":"10774_CR311","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/jgh.14538","volume":"34","author":"S Koya","year":"2019","unstructured":"Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E, et al. Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2019;34(3):580\u2013588","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR312","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1111\/hepr.12718","volume":"47","author":"S Koya","year":"2017","unstructured":"Koya S, Kawaguchi T, Hashida R, Goto E, Matsuse H, Saito H, et al. Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease. Hepatol Res. 2017;47(3):E22\u2013E34","journal-title":"Hepatol Res"},{"issue":"11","key":"10774_CR313","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/bjs.9258","volume":"100","author":"N Harimoto","year":"2013","unstructured":"Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100(11):1523\u20131530","journal-title":"Br J Surg"},{"issue":"12","key":"10774_CR314","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/hepr.12674","volume":"46","author":"N Harimoto","year":"2016","unstructured":"Harimoto N, Yoshizumi T, Shimokawa M, Sakata K, Kimura K, Itoh S, et al. Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res. 2016;46(12):1247\u20131255","journal-title":"Hepatol Res"},{"issue":"2","key":"10774_CR315","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3892\/ol.2017.6287","volume":"14","author":"H Nishikawa","year":"2017","unstructured":"Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett. 2017;14(2):1637\u20131647","journal-title":"Oncol Lett"},{"issue":"3","key":"10774_CR316","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4143\/crt.2017.232","volume":"50","author":"Y Ha","year":"2018","unstructured":"Ha Y, Kim D, Han S, Chon YE, Lee YB, Kim MN, et al. Sarcopenia predicts prognosis in patients with newly diagnosed hepatocellular carcinoma, independent of tumor stage and liver function. Cancer Res Treat. 2018;50(3):843\u2013851","journal-title":"Cancer Res Treat"},{"issue":"10","key":"10774_CR317","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/nu9101054","volume":"9","author":"K Imai","year":"2017","unstructured":"Imai K, Takai K, Watanabe S, Hanai T, Suetsugu A, Shiraki M, et al. Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: the role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume. Nutrients. 2017;9(10):1054","journal-title":"Nutrients"},{"issue":"6","key":"10774_CR318","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198812","volume":"13","author":"H Takada","year":"2018","unstructured":"Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, et al. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE. 2018;13(6): e0198812","journal-title":"PLoS ONE"},{"issue":"1","key":"10774_CR319","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12876-019-1152-4","volume":"19","author":"Y Mardian","year":"2019","unstructured":"Mardian Y, Yano Y, Ratnasari N, Choridah L, Wasityastuti W, Setyawan NH, et al. Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study. BMC Gastroenterol. 2019;19(1):229","journal-title":"BMC Gastroenterol"},{"key":"10774_CR320","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2147\/JHC.S418885","volume":"10","author":"Q Kong","year":"2023","unstructured":"Kong Q, Yi M, Teng F, Li H, Chen Z. Sarcopenia imperils postoperative long-term survival in HCC patients with metabolic dysfunction-associated fatty liver disease: a propensity score matching analysis. J Hepatocell Carcinoma. 2023;10:1367\u20131377","journal-title":"J Hepatocell Carcinoma."},{"issue":"7","key":"10774_CR321","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/hepr.13667","volume":"51","author":"S Yoshio","year":"2021","unstructured":"Yoshio S, Shimagaki T, Hashida R, Kawaguchi T, Tsutsui Y, Sakamoto Y, et al. Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. Hepatol Res. 2021;51(7):803\u2013812","journal-title":"Hepatol Res"},{"issue":"3","key":"10774_CR322","first-page":"2355","volume":"19","author":"R Hashida","year":"2020","unstructured":"Hashida R, Kawaguchi T, Koya S, Hirota K, Goshima N, Yoshiyama T, et al. Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. Oncol Lett. 2020;19(3):2355\u20132367","journal-title":"Oncol Lett"},{"issue":"3","key":"10774_CR323","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00535-023-02060-0","volume":"59","author":"T Kawaguchi","year":"2023","unstructured":"Kawaguchi T, Kawaguchi A, Hashida R, Nakano D, Tsutsumi T, Kawaguchi M, et al. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol. 2023;59(3):216\u201328.","journal-title":"J Gastroenterol"},{"issue":"4","key":"10774_CR324","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3350\/cmh.2021.0258","volume":"27","author":"S Shimose","year":"2021","unstructured":"Shimose S, Koya S, Kawaguchi T, Hirota K, Yoshio S, Niizeki T, et al. Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(4):616\u2013619","journal-title":"Clin Mol Hepatol"},{"issue":"7854","key":"10774_CR325","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumor surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u2013456","journal-title":"Nature"},{"issue":"6","key":"10774_CR326","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6): 100591","journal-title":"ESMO Open."},{"issue":"2","key":"10774_CR327","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/hepr.13843","volume":"53","author":"S Shimose","year":"2023","unstructured":"Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, et al. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2023;53(2):104\u2013115","journal-title":"Hepatol Res"},{"issue":"6","key":"10774_CR328","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100330","volume":"6","author":"M Rimini","year":"2021","unstructured":"Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021;6(6): 100330","journal-title":"ESMO Open."},{"issue":"1","key":"10774_CR329","doi-asserted-by":"publisher","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","volume":"8","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, et al. The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2024;8(1):e0352","journal-title":"Hepatol Commun"},{"issue":"1","key":"10774_CR330","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/LVT.0000000000000007","volume":"29","author":"EC Verna","year":"2023","unstructured":"Verna EC, Phipps MM, Halazun KJ, Markovic D, Florman SS, Haydel BM, et al. Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium. Liver Transpl. 2023;29(1):34\u201347","journal-title":"Liver Transpl"},{"issue":"12","key":"10774_CR331","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/tri.14158","volume":"34","author":"VXY Teo","year":"2021","unstructured":"Teo VXY, Heng RRY, Tay PWL, Ng CH, Tan DJH, Ong Y, et al. A meta-analysis on the prevalence of chronic kidney disease in liver transplant candidates and its associated risk factors and outcomes. Transpl Int. 2021;34(12):2515\u20132523","journal-title":"Transpl Int"},{"key":"10774_CR332","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.599434","volume":"7","author":"PJ Hegyi","year":"2020","unstructured":"Hegyi PJ, Soos A, Hegyi P, Szakacs Z, Hanak L, Vancsa S, et al. Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and a systematic review. Front Med (Lausanne). 2020;7: 599434","journal-title":"Front Med (Lausanne)."},{"key":"10774_CR333","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691","journal-title":"Gut"},{"issue":"10","key":"10774_CR334","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1097\/TP.0000000000004208","volume":"106","author":"OK Jamil","year":"2022","unstructured":"Jamil OK, Sandikci B, Faust N, Cotter TG, Paul S, di Sabato D, et al. Relatively poor long-term outcomes following liver transplantation for NASH in the United States. Transplantation. 2022;106(10):2006\u20132018","journal-title":"Transplantation"},{"issue":"2","key":"10774_CR335","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol. 2019;71(2):313\u2013322","journal-title":"J Hepatol"},{"issue":"6","key":"10774_CR336","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1002\/hep.31647","volume":"73","author":"PM Barman","year":"2021","unstructured":"Barman PM, VanWagner LB. Cardiac risk assessment in liver transplant candidates: current controversies and future directions. Hepatology. 2021;73(6):2564\u20132576","journal-title":"Hepatology"},{"issue":"4","key":"10774_CR337","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jhep.2023.05.034","volume":"79","author":"WH Lim","year":"2023","unstructured":"Lim WH, Ng CH, Tan D, Tseng M, Xiao J, Yong JN, et al. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023;79(4):1015\u20131024","journal-title":"J Hepatol"},{"issue":"1","key":"10774_CR338","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/TP.0000000000002466","volume":"103","author":"I Linares","year":"2019","unstructured":"Linares I, Hamar M, Selzner N, Selzner M. Steatosis in liver transplantation: current limitations and future strategies. Transplantation. 2019;103(1):78\u201390","journal-title":"Transplantation"},{"issue":"24","key":"10774_CR339","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3748\/wjg.v27.i24.3682","volume":"27","author":"S Trakroo","year":"2021","unstructured":"Trakroo S, Bhardwaj N, Garg R, Modaresi EJ. Weight loss interventions in living donor liver transplantation as a tool in expanding the donor pool: a systematic review and meta-analysis. World J Gastroenterol. 2021;27(24):3682\u20133692","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10774_CR340","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001431","volume":"9","author":"JS Lin","year":"2023","unstructured":"Lin JS, Muhammad H, Lin T, Kamel I, Baghdadi A, Rizkalla N, et al. Donor BMI and post-living donor liver transplantation outcomes: a preliminary report. Transpl Direct. 2023;9(2): e1431","journal-title":"Transpl Direct."},{"issue":"4","key":"10774_CR341","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ags3.12658","volume":"7","author":"R Goto","year":"2023","unstructured":"Goto R, Kawamura N, Watanabe M, Ganchiku Y, Nagatsu A, Okada K, et al. Long-term risk of a fatty liver in liver donors. Ann Gastroenterol Surg. 2023;7(4):645\u2013653","journal-title":"Ann Gastroenterol Surg."},{"issue":"4","key":"10774_CR342","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/LVT.0000000000000245","volume":"30","author":"M Akabane","year":"2023","unstructured":"Akabane M, Imaoka Y, Esquivel CO, Melcher ML, Kwong A, Sasaki K. Overcoming the hurdles of steatotic grafts in liver transplantation: Insights into survival and prognostic factors. Liver Transpl. 2023;30(4):376\u201385.","journal-title":"Liver Transpl"},{"issue":"17","key":"10774_CR343","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/jcm11175218","volume":"11","author":"J Widmer","year":"2022","unstructured":"Widmer J, Eden J, Carvalho MF, Dutkowski P, Schlegel A. Machine perfusion for extended criteria donor livers: what challenges remain? J Clin Med. 2022;11(17):5218","journal-title":"J Clin Med"},{"issue":"2","key":"10774_CR344","first-page":"473","volume":"108","author":"WH Lim","year":"2024","unstructured":"Lim WH, Ng CH, Tan DJH, Xiao J, Fu CE, Ong C, et al. Donor diabetes and steatosis affects recipient survival following liver transplantation based on etiology of liver cirrhosis. Transplantation. 2024;108(2):473\u2013482","journal-title":"Transplantation"},{"issue":"5","key":"10774_CR345","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jceh.2023.03.013","volume":"13","author":"S Taneja","year":"2023","unstructured":"Taneja S, Roy A, Duseja A. NASH after liver transplantation: impact of immunosuppression. J Clin Exp Hepatol. 2023;13(5):835\u2013840","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10774_CR346","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100192","volume":"2","author":"P Burra","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2020;2(6): 100192","journal-title":"JHEP Rep."},{"issue":"7","key":"10774_CR347","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.14309\/ajg.0000000000001176","volume":"116","author":"HK Tan","year":"2021","unstructured":"Tan HK, Teng MLP, Soh AYS, Cheo SHY, Fook-Chong S, Goh GBB, et al. Poor outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with hepatitis b after decompensation with ascites. Am J Gastroenterol. 2021;116(7):1437\u20131446","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10774_CR348","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1097\/HEP.0000000000000456","volume":"80","author":"M Mallet","year":"2023","unstructured":"Mallet M, Silaghi CA, Sultanik P, Conti F, Rudler M, Ratziu V, et al. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology. 2023;80(5):1270\u201390.","journal-title":"Hepatology"},{"issue":"11","key":"10774_CR349","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20(11):708\u2013722","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR350","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17474124.2020.1731303","volume":"14","author":"O El Sherif","year":"2020","unstructured":"El Sherif O, Dhaliwal A, Newsome PN, Armstrong MJ. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14(3):197\u2013205","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR351","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172\u2013193","journal-title":"J Hepatol"},{"issue":"4","key":"10774_CR352","doi-asserted-by":"publisher","first-page":"e0108","DOI":"10.1097\/HC9.0000000000000108","volume":"7","author":"JG Stine","year":"2023","unstructured":"Stine JG, Long MT, Corey KE, Sallis RE, Allen AM, Armstrong MJ, et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatol Commun. 2023;7(4):e0108","journal-title":"Hepatol Commun"},{"issue":"12","key":"10774_CR353","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/17474124.2020.1810563","volume":"14","author":"T Fernandez-Mincone","year":"2020","unstructured":"Fernandez-Mincone T, Contreras-Briceno F, Espinosa-Ramirez M, Garcia-Valdes P, Lopez-Fuenzalida A, Riquelme A, et al. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2020;14(12):1141\u20131157","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR354","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.28992","volume":"65","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A, Augustin S, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65(4):1293\u20131305","journal-title":"Hepatology"},{"issue":"10","key":"10774_CR355","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","volume":"20","author":"O Bassegoda","year":"2022","unstructured":"Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L, et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease. Clin Gastroenterol Hepatol. 2022;20(10):2276\u20132286","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10774_CR356","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","volume":"9","author":"JD Mosko","year":"2011","unstructured":"Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(10):897\u2013901","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"28","key":"10774_CR357","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3748\/wjg.v24.i28.3112","volume":"24","author":"GB Goh","year":"2018","unstructured":"Goh GB, Schauer PR, McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World J Gastroenterol. 2018;24(28):3112\u20133119","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10774_CR358","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cgh.2020.10.034","volume":"19","author":"H Patton","year":"2021","unstructured":"Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: expert review. Clin Gastroenterol Hepatol. 2021;19(3):436\u2013445","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10774_CR359","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864\u2013873","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"10774_CR360","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/ijms17060947","volume":"17","author":"JL Temple","year":"2016","unstructured":"Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6):947","journal-title":"Int J Mol Sci"},{"key":"10774_CR361","doi-asserted-by":"publisher","first-page":"204201882311603","DOI":"10.1177\/20420188231160388","volume":"14","author":"R Hegarty","year":"2023","unstructured":"Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A. Fatty liver disease in children (MAFLD\/PeFLD type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388","journal-title":"Ther Adv Endocrinol Metab."},{"issue":"7","key":"10774_CR362","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.medj.2024.03.017","volume":"5","author":"L Zhang","year":"2024","unstructured":"Zhang L, El-Shabrawi M, Baur LA, Byrne CD, Targher G, Kehar M, et al. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med. 2024;5(7):797-815.e2.","journal-title":"Med"},{"issue":"5","key":"10774_CR363","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/biomedicines10051184","volume":"10","author":"L Carrieri","year":"2022","unstructured":"Carrieri L, Osella AR, Ciccacci F, Giannelli G, Scavo MP. Premenopausal syndrome and NAFLD: a new approach based on gender medicine. Biomedicines. 2022;10(5):1184","journal-title":"Biomedicines."},{"key":"10774_CR364","doi-asserted-by":"publisher","first-page":"204201882412525","DOI":"10.1177\/20420188241252543","volume":"15","author":"Z Pan","year":"2024","unstructured":"Pan Z, Khatry MA, Yu M-L, Choudhury A, Sebastiani G, Alqahtani SA, et al. MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight. Therapeutic Adv Endocrinol Metab. 2024;15:20420188241252544","journal-title":"Therapeutic Adv Endocrinol Metab"},{"issue":"2","key":"10774_CR365","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5009\/gnl210084","volume":"16","author":"Y Kim","year":"2022","unstructured":"Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290\u2013299","journal-title":"Gut Liver."},{"issue":"8","key":"10774_CR366","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S2468-1253(20)30090-X","volume":"5","author":"M Eslam","year":"2020","unstructured":"Eslam M, Fan J-G, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol. 2020;5(8):713\u2013715","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR367","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-022-02716-3","volume":"21","author":"GE Chung","year":"2023","unstructured":"Chung GE, Yu SJ, Yoo JJ, Cho Y, Lee KN, Shin DW, et al. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Med. 2023;21(1):4","journal-title":"BMC Med"},{"issue":"5","key":"10774_CR368","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s12072-024-10701-6","volume":"18","author":"M Alarabi","year":"2024","unstructured":"Alarabi M, Pan Z, Romero-G\u00f3mez M, George J, Eslam M. Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation. Hepatol Int. 2024;18(5):1448\u201358.","journal-title":"Hepatol Int"},{"key":"10774_CR369","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155583","volume":"144","author":"J Alharthi","year":"2023","unstructured":"Alharthi J, Pan Z, Gloss BS, McLeod D, Weltman M, George J, et al. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism. 2023;144: 155583","journal-title":"Metabolism"},{"issue":"10","key":"10774_CR370","first-page":"1352","volume":"32","author":"E Kaya","year":"2019","unstructured":"Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroen Hepat. 2019;32(10):1352\u20137.","journal-title":"Eur J Gastroen Hepat"},{"issue":"9","key":"10774_CR371","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/j.1440-1746.2008.05531.x","volume":"23","author":"JP Shi","year":"2008","unstructured":"Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23(9):1419\u20131425","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10774_CR372","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862\u2013873","journal-title":"J Hepatol"},{"issue":"5","key":"10774_CR373","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","volume":"12","author":"D Hu","year":"2018","unstructured":"Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12(5):438\u2013446","journal-title":"Hepatol Int"},{"issue":"9","key":"10774_CR374","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/apt.16595","volume":"54","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1100\u20131109","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10774_CR375","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/liv.13271","volume":"37","author":"P Charatcharoenwitthaya","year":"2017","unstructured":"Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542\u2013551","journal-title":"Liver Int"},{"issue":"2","key":"10774_CR376","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539\u2013548","journal-title":"Hepatology"},{"issue":"1","key":"10774_CR377","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jgh.16363","volume":"39","author":"CF Huang","year":"2024","unstructured":"Huang CF, Liang PC, Tsai PC, Wei YJ, Huang CI, Wang CW, et al. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: a large community-based study in a viral endemic area. J Gastroenterol Hepatol. 2024;39(1):193\u2013201","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10774_CR378","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3350\/cmh.2023.0004","volume":"29","author":"YJ Wong","year":"2023","unstructured":"Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29(3):705\u2013720","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10774_CR379","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis b surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224(2):294\u2013302","journal-title":"J Infect Dis"},{"issue":"4","key":"10774_CR380","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-021-10205-7","volume":"15","author":"JH Oh","year":"2021","unstructured":"Oh JH, Lee HW, Sinn DH, Park JY, Kim BK, Kim SU, et al. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int. 2021;15(4):892\u2013900","journal-title":"Hepatol Int"},{"issue":"4","key":"10774_CR381","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","volume":"15","author":"LY Mak","year":"2021","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15(4):901\u2013911","journal-title":"Hepatol Int"},{"key":"10774_CR382","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","volume":"22","author":"MH Lee","year":"2024","unstructured":"Lee MH, Chen YT, Huang YH, Lu SN, Yang TH, Huang JF, et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastroenterol Hepatol Off Clin Practice J Am Gastroenterological Association. 2024;22:1275","journal-title":"Clin Gastroenterol Hepatol Off Clin Practice J Am Gastroenterological Association."},{"issue":"3","key":"10774_CR383","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533\u2013540","journal-title":"J Hepatol"},{"issue":"3","key":"10774_CR384","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65(3):828\u2013835","journal-title":"Hepatology"},{"issue":"9","key":"10774_CR385","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361\u20131367","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR386","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40121-022-00725-6","volume":"12","author":"Y Diao","year":"2023","unstructured":"Diao Y, Tang J, Wang X, Deng W, Tang J, You C. Metabolic syndrome, nonalcoholic fatty liver disease, and chronic hepatitis B: a narrative review. Infect Dis Ther. 2023;12(1):53\u201366","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10774_CR387","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3350\/cmh.2018.0054","volume":"25","author":"DS Kim","year":"2019","unstructured":"Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. Clin Mol Hepatol. 2019;25(3):283\u2013293","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10774_CR388","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/hep.32716","volume":"77","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Lee CH, Mao X, Cheung KS, Wong DK, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology. 2023;77(2):606\u2013618","journal-title":"Hepatology"},{"issue":"2","key":"10774_CR389","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/apt.17765","volume":"59","author":"PN Cheng","year":"2024","unstructured":"Cheng PN, Feng IC, Chen JJ, Kuo HT, Lee PL, Yu ML, et al. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2024;59(2):230\u2013238","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10774_CR390","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jfma.2021.09.009","volume":"121","author":"ML Yeh","year":"2022","unstructured":"Yeh ML, Liang PC, Trinh S, Huang CI, Huang CF, Hsieh MY, et al. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide(\u2606). J Formos Med Assoc. 2022;121(7):1273\u20131282","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"10774_CR391","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1007\/s11695-022-05979-0","volume":"32","author":"CM Tai","year":"2022","unstructured":"Tai CM, Tu HP, Hwang JC, Yeh ML, Huang CF, Yu ML. HBV reactivation after bariatric surgery for HBV-infected obese patients. Obes Surg. 2022;32(10):3332\u20133339","journal-title":"Obes Surg"},{"issue":"11\u201312","key":"10774_CR392","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/apt.17233","volume":"56","author":"D Attia","year":"2022","unstructured":"Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Alimentary Pharmacol Therap. 2022;56(11\u201312):1581\u20131590","journal-title":"Alimentary Pharmacol Therap"},{"issue":"1","key":"10774_CR393","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jfma.2023.07.010","volume":"123","author":"KL Cheng","year":"2024","unstructured":"Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. 2024 Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formosan Med Assoc = Taiwan yi zhi. 2024;123(1):36\u201344","journal-title":"J Formosan Med Assoc = Taiwan yi zhi"},{"issue":"2","key":"10774_CR394","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","volume":"126","author":"A Lonardo","year":"2004","unstructured":"Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126(2):586\u2013597","journal-title":"Gastroenterology"},{"issue":"3","key":"10774_CR395","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2014.10.011","volume":"62","author":"CF Huang","year":"2015","unstructured":"Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62(3):512\u2013518","journal-title":"J Hepatol"},{"issue":"8","key":"10774_CR396","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/01.mcg.0000135372.10846.2a","volume":"38","author":"ZM Younossi","year":"2004","unstructured":"Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38(8):705\u2013709","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"10774_CR397","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","volume":"24","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol. 2018;24(11):1269\u20131277","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10774_CR398","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/apt.16346","volume":"53","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Lazarus JV, Negro F, Peck-Radosavljevic M, Sarin SK, Ferenci P, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Alimentary Pharmacol Therap. 2021;53(10):1080\u20131089","journal-title":"Alimentary Pharmacol Therap"},{"issue":"6","key":"10774_CR399","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/liv.13633","volume":"38","author":"YH Yen","year":"2018","unstructured":"Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, et al. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018;38(6):1064\u20131073","journal-title":"Liver Int"},{"key":"10774_CR400","first-page":"1075","volume":"4","author":"A Cespiati","year":"2024","unstructured":"Cespiati A, Coelho Rodrigues I, Santos I, Policarpo S, Carvalhana S, Fracanzani AL, et al. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: a systematic review. Liver Int Off J Int Association Study Liver. 2024;4:1075","journal-title":"Liver Int Off J Int Association Study Liver"},{"issue":"11","key":"10774_CR401","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/kjm2.12275","volume":"36","author":"CF Huang","year":"2020","unstructured":"Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, et al. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36(11):920\u2013928","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"10774_CR402","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12072-023-10576-z","volume":"18","author":"CI Shih","year":"2024","unstructured":"Shih CI, Wu KT, Hsieh MH, Yang JF, Chen YY, Tsai WL, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2024;18(1):138\u2013154","journal-title":"Hepatol Int"},{"issue":"2","key":"10774_CR403","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","volume":"78","author":"PC Tsai","year":"2023","unstructured":"Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, et al. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan. J Hepatol. 2023;78(2):281\u2013292","journal-title":"J Hepatol"},{"issue":"7","key":"10774_CR404","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","volume":"21","author":"M Kalligeros","year":"2023","unstructured":"Kalligeros M, Vassilopoulos A, Shehadeh F, Vassilopoulos S, Lazaridou I, Mylonakis E, et al. Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1708\u20131722","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10774_CR405","doi-asserted-by":"publisher","first-page":"9158","DOI":"10.1038\/s41598-023-32965-y","volume":"13","author":"M Michel","year":"2023","unstructured":"Michel M, Labenz C, Armandi A, Kaps L, Kremer WM, Galle PR, et al. Metabolic dysfunction-associated fatty liver disease in people living with HIV. Sci Rep. 2023;13(1):9158","journal-title":"Sci Rep"},{"key":"10774_CR406","doi-asserted-by":"crossref","unstructured":"Eslam M, George J. Two years on, a perspective on MAFLD. eGastroenterology. 2023;1(2)","DOI":"10.1136\/egastro-2023-100019"},{"issue":"17","key":"10774_CR407","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.2169\/internalmedicine.54.2736","volume":"54","author":"M Hirakawa","year":"2015","unstructured":"Hirakawa M, Arase Y, Amakawa K, Ohmoto-Sekine Y, Ishihara M, Shiba M, et al. Relationship between alcohol intake and risk factors for metabolic syndrome in men. Int Med. 2015;54(17):2139\u20132145","journal-title":"Int Med"},{"key":"10774_CR408","first-page":"2104","volume":"23","author":"SK Kim","year":"2017","unstructured":"Kim SK, Hong S-H, Chung J-H, Cho KB. Association between alcohol consumption and metabolic syndrome in a community-based cohort of Korean adults. Med Scie Monit Int Med J Exp Clin Res. 2017;23:2104","journal-title":"Med Scie Monit Int Med J Exp Clin Res"},{"issue":"3","key":"10774_CR409","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/hep.30864","volume":"71","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg F, Puukka P, Salomaa V, M\u00e4nnist\u00f6 S, Lundqvist A, Valsta L, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71(3):835\u2013848","journal-title":"Hepatology"},{"issue":"10347","key":"10774_CR410","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","volume":"400","author":"D Bryazka","year":"2022","unstructured":"Bryazka D, Reitsma MB, Griswold MG, Abate KH, Abbafati C, Abbasi-Kangevari M, et al. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet. 2022;400(10347):185\u2013235","journal-title":"Lancet"},{"issue":"2","key":"10774_CR411","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187\u2013194","journal-title":"Curr Obes Rep"},{"issue":"10","key":"10774_CR412","doi-asserted-by":"publisher","DOI":"10.2196\/40238","volume":"24","author":"M Sharma","year":"2022","unstructured":"Sharma M, Savage C, Nair M, Larsson I, Svedberg P, Nygren JM. Artificial intelligence applications in health care practice: scoping review. J Med Internet Res. 2022;24(10): e40238","journal-title":"J Med Internet Res"},{"issue":"3","key":"10774_CR413","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1148\/radiol.2020190283","volume":"295","author":"AM Rauschecker","year":"2020","unstructured":"Rauschecker AM, Rudie JD, Xie L, Wang J, Duong MT, Botzolakis EJ, et al. Artificial intelligence system approaching neuroradiologist-level differential diagnosis accuracy at brain MRI. Radiology. 2020;295(3):626\u2013637","journal-title":"Radiology"},{"issue":"5","key":"10774_CR414","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","volume":"38","author":"A Lonardo","year":"2021","unstructured":"Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Adv Ther. 2021;38(5):2130\u20132158","journal-title":"Adv Ther"},{"issue":"9","key":"10774_CR415","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/diagnostics10090643","volume":"10","author":"W-Q Leow","year":"2020","unstructured":"Leow W-Q, Bedossa P, Liu F, Wei L, Lim K-H, Wan W-K, et al. An improved qFibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis (NASH) clinical trials. Diagnostics. 2020;10(9):643","journal-title":"Diagnostics"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10774-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10774-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10774-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T03:02:29Z","timestamp":1744772549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10774-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":415,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10774"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10774-3","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LAA has served as an advisory board member or speaker for Novo Nordisk, CSL Behring and Gilead. ME has received personal fees from Pfizer and honoraria from Sanofi. JG is on advisory boards and receives honoraria for talks from Novo Nordisk, AstraZeneca, Roche, BMS, Pfizer, Cincera, Pharmaxis and Boehringer Mannheim.\u00a0JH has received competitive grant funding from Gilead Sciences and speaker fee and ad board support from Roche and Astra-Zeneca, none relevant to this clinical guideline. JFH has received research grant from Gilead, Bristol-Myer-Squibb, serves as a consultant for Roche, Sysmex, Boehringer Ingelheim, Aligos, and has been a speaker for AbbVie, Gilead, Merck, Sysmex, and Novo Nordisk. WK has received honoraria and served in an advisory role for Gilead, Boehringer-Ingelheim, GSK, Novo Nordisk, Samil, Ildong, LG Chemistry, YUHAN, Hanmi, HK Inoen, Standigm, PharmaKing, KOBIOLABS, Olix Pharma, TSD Life Sciences, Daewoong, QUEST, Therasid Bioscience, Korea United Pharm, and Eisai; has received research funding from GSK, Gilead, Novartis, Pfizer, Roche, Springbank, Altimmune, Ildong, DaeWoong, Dicerna, Celgene, Hanmi, Novo Nordisk, Galmed, Enyo. TK received lecture fees from ASKA Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., AbbVie GK., Eisai Co., Ltd., Novo Nordisk Pharma Ltd., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd. and KOBIOLABS; holds stock in KOBIOLABS and Lepidyne; and is the founder of Remedygen Incorporation. SKR is a member of the Advisory Board for Novo Nordisk. The other authors disclose no conflicts. SIS has received honoraria for advisory boards or speaking from Roche, Astra Zeneca, Ipsen, Eisai, Sirtex, BMS, MSD, AbbVie, Gilead Sciences, Norgine, Astellas, Novartis, Pfizer, CSL-Behring, Dr Falk Pharma, Chiesi, Novo Nordisk. WKS received speaker\u2019s fees from Echosens, is an advisory board member and received speaker's fees from Abbott, received research funding from Astrazeneca, Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer and Ribo Life Science, and is an advisory board member, received speaker\u2019s fees and research funding from Gilead Sciences. VW has provided consultancy services to AbbVie, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Intercept, Inventiva, Merck, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna; has delivered lectures for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk, and Unilab; has received research grants from Gilead Sciences; and he is a co-founder of Illuminatio Medical Technology, in which he holds stock. MLY has research support from Abbvie, Abbott Diagnostic, BMS, Gilead, Merck and Roche diagnostics; served as a consultant of Abbott, Abbvie, Abbott Diagnostic, BMS, Gilead, Roche and Roche diagnostics and a speaker of Abbvie, BMS, Eisai, Gilead, Roche and Roche diagnostics. YY has served as a consultant for Zydus, Cymabay, and Novo Nordisk, and as a speaker for Echosens. MHZ has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, consulting fees from Boehringer Ingelheim. Outside their participation in this work. The other authors disclose no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent."}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}